ArticleBioanalysis2025
Pharmacokinetic-pharmacodynamic and tissue distribution studies in physiological and cerebral ischemia-reperfusion injury rats after oral administration of anisodine hydrobromide tablets.
Article in Bioanalysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anisodine hydrobromide targets matk and prevents delayed rtPA thrombolysis-induced vasogenic cerebral edema in ischemic stroke.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimWe aim to establish a rapid and sensitive UPLC-MS/MS method to analyze the pharmacokinetics of oral anisodine hydrobromide (AH) tablets.
methodsComparison of pharmacokinetic differences between AH (present in vivo as anisodine) and its metabolite NOAT3 in two groups of rats after administration of AH at doses of 5, 10, and 20 mg/kg. In addition, plasma concentrations of AH were used as a pharmacokinetic parameter, and interleukin-1β (IL-1β) and lactic dehydrogenase (LDH) were selected as pharmacodynamic indicators to establish a pharmacokinetics-pharmacodynamics (PK-PD) combined model in physiological and CIRI model rats, to analyze the protective effect of AH against CIRI. RESULTS &
conclusionThe study demonstrated that AH could be rapidly and extensively distributed to various tissues in rats. AH is a promising drug for the treatment of rat models of CIRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.